New pill could help LADA patients keep making insulin longer
NCT ID NCT07460336
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug cofrogliptin to standard treatment (metformin, insulin, and vitamin D3) can help preserve beta-cell function in adults with latent autoimmune diabetes (LADA). Over 52 weeks, 84 participants will take either cofrogliptin or a placebo, and researchers will measure changes in insulin production using a mixed-meal test. The goal is to see if cofrogliptin can slow the loss of the body's ability to make insulin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cofrogliptin
- What this could lead to
- If it works, this could point toward a way to preserve insulin production in people with LADA, potentially delaying the need for insulin therapy.
- What could go wrong
- This is a small, early-stage trial with only 84 participants, and it is not yet recruiting. The results may not apply to all LADA patients, and the drug may not show significant benefit over standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Xiangya Hospital, Central South University
Changsha, Hunan, 410000, China